Compare Abeona Therapeutics Inc (ABEO) vs American International Group Inc (AIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American International Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while American International Group Inc trades at $80.31 (market cap $42.98B). The key difference: American International Group Inc is far larger — about 115.1× Abeona Therapeutics Inc's market cap, and American International Group Inc pays a 2.47% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AIG | |
|---|---|---|
Market Cap | $373.32M | $42.98B |
Sector | Health | Financials |
52-Week High | $7.23 | $86.59 |
52-Week Low | $4.17 | $71.89 |
Enterprise Value | $228.22M | $50.68B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →
